Why is Innoviva, Inc. ?
1
High Management Efficiency with a high ROCE of 30.79%
2
Strong ability to service debt as the company has a low Debt to EBITDA ratio of 0.93 times
3
Poor long term growth as Operating profit has grown by an annual rate -9.22% of over the last 5 years
4
Positive results in Jun 25
- OPERATING CASH FLOW(Y) Highest at USD 200.62 MM
- DEBT-EQUITY RATIO (HY) Lowest at 2.74 %
- INTEREST COVERAGE RATIO(Q) Highest at 1,260.69
5
With ROCE of 28.07%, it has a risky valuation with a 3.15 Enterprise value to Capital Employed
- The stock is trading at a premium compared to its peers' average historical valuations
- Over the past year, while the stock has generated a return of 13.18%, its profits have risen by 73.3% ; the PEG ratio of the company is 0.2
6
High Institutional Holdings at 100%
- These investors have better capability and resources to analyse fundamentals of companies than most retail investors.
7
Market Beating performance in long term as well as near term
- Along with generating 13.18% returns in the last 1 year, the stock has outperformed S&P 500 in the last 3 years, 1 year and 3 months
How much should you hold?
- Overall Portfolio exposure to Innoviva, Inc. should be less than 10%
- Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)
When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock
Is Innoviva, Inc. for you?
Low Risk, High Return
Absolute
Risk Adjusted
Volatility
Innoviva, Inc.
9.53%
1.39
26.09%
S&P 500
13.22%
0.61
20.17%
Quality key factors
Factor
Value
Sales Growth (5y)
4.16%
EBIT Growth (5y)
-9.22%
EBIT to Interest (avg)
12.42
Debt to EBITDA (avg)
0.93
Net Debt to Equity (avg)
0.01
Sales to Capital Employed (avg)
0.31
Tax Ratio
28.92%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
100.00%
ROCE (avg)
30.79%
ROE (avg)
41.84%
Valuation Key Factors 
Factor
Value
P/E Ratio
15
Industry P/E
Price to Book Value
3.16
EV to EBIT
11.23
EV to EBITDA
9.21
EV to Capital Employed
3.15
EV to Sales
5.34
PEG Ratio
0.20
Dividend Yield
NA
ROCE (Latest)
28.07%
ROE (Latest)
20.43%
Technical key factors
Indicator
Weekly
Monthly
MACD
Bullish
Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bullish
Bullish
Moving Averages
Mildly Bearish (Daily)
KST
Mildly Bullish
Mildly Bearish
Dow Theory
No Trend
Mildly Bullish
OBV
No Trend
Mildly Bearish
Technical Movement
10What is working for the Company
OPERATING CASH FLOW(Y)
Highest at USD 200.62 MM
DEBT-EQUITY RATIO
(HY)
Lowest at 2.74 %
INTEREST COVERAGE RATIO(Q)
Highest at 1,260.69
CASH AND EQV(HY)
Highest at USD 944.61 MM
NET SALES(Q)
Highest at USD 103.74 MM
EPS(Q)
Highest at USD 0.77
0What is not working for the Company
NO KEY NEGATIVE TRIGGERS
Here's what is working for Innoviva, Inc.
Operating Cash Flow
Highest at USD 200.62 MM and Grown
In each year in the last three yearsMOJO Watch
The company has generated higher cash revenues from business operations
Operating Cash Flows (USD MM)
Interest Coverage Ratio
Highest at 1,260.69
in the last five periodsMOJO Watch
The company's ability to manage interest payments is improving
Operating Profit to Interest
Debt-Equity Ratio
Lowest at 2.74 % and Grown
In each half year in the last five Semi-Annual periodsMOJO Watch
The company has been reducing its borrowing as compared to equity capital
Debt-Equity Ratio
Net Sales
Highest at USD 103.74 MM
in the last five periodsMOJO Watch
Near term sales trend is positive
Net Sales (USD MM)
EPS
Highest at USD 0.77
in the last five periodsMOJO Watch
Increasing profitability; company has created higher earnings for shareholders
EPS (USD)
Cash and Eqv
Highest at USD 944.61 MM
in the last six Semi-Annual periodsMOJO Watch
Short Term liquidity is improving
Cash and Cash Equivalents
Depreciation
Highest at USD 10.04 MM
in the last five periodsMOJO Watch
The expenditure on assets done by the company may have gone into operation
Depreciation (USD MM)






